BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation. Dermatology. 2015;231:184-190. [PMID: 26139027 DOI: 10.1159/000431175] [Cited by in Crossref: 136] [Cited by in F6Publishing: 107] [Article Influence: 22.7] [Reference Citation Analysis]
Number Citing Articles
1 Sabat R, Tsaousi A, Rossbacher J, Kurzen H, Fadai T, Schwichtenberg U, Schneider-Burrus S, Kokolakis G, Wolk K. [Acne inversa/hidradenitis suppurativa: An update]. Hautarzt 2017;68:999-1006. [PMID: 29159469 DOI: 10.1007/s00105-017-4082-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
2 Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol 2021. [PMID: 34378812 DOI: 10.1111/jdv.17598] [Reference Citation Analysis]
3 Giamarellos-Bourboulis EJ, Platzer M, Karagiannidis I, Kanni T, Nikolakis G, Ulrich J, Bellutti M, Gollnick H, Bauer M, Zouboulis CC, Huse K. High Copy Numbers of β-Defensin Cluster on 8p23.1, Confer Genetic Susceptibility, and Modulate the Physical Course of Hidradenitis Suppurativa/Acne Inversa. J Invest Dermatol 2016;136:1592-8. [PMID: 27164300 DOI: 10.1016/j.jid.2016.04.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
4 Iida T, Hida T, Matsuura M, Uhara H, Nakase H. Current clinical issue of skin lesions in patients with inflammatory bowel disease. Clin J Gastroenterol 2019;12:501-10. [PMID: 30838512 DOI: 10.1007/s12328-019-00958-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Krajewski PK, Matusiak Ł, von Stebut E, Schultheis M, Kirschner U, Nikolakis G, Szepietowski JC. Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients. Life (Basel) 2021;11:34. [PMID: 33429896 DOI: 10.3390/life11010034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Ovadja ZN, Schuit MM, van der Horst CMAM, Lapid O. Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa. Br J Dermatol 2019;181:344-9. [PMID: 30585304 DOI: 10.1111/bjd.17588] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Jørgensen AR, Holm JG, Ghazanfar MN, Yao Y, Ring HC, Thomsen SF. Factors affecting quality of life in patients with hidradenitis suppurativa. Arch Dermatol Res 2020;312:427-36. [PMID: 31848682 DOI: 10.1007/s00403-019-02025-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
8 Collier EK, Parvataneni RK, Lowes MA, Naik HB, Okun M, Shi VY, Hsiao JL. Diagnosis and management of hidradenitis suppurativa in women. Am J Obstet Gynecol 2021;224:54-61. [PMID: 32980357 DOI: 10.1016/j.ajog.2020.09.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Loget J, Saint-Martin C, Guillem P, Kanagaratnam L, Becherel PA, Nassif A, Fougerousse AC, Siham M, Girard C, Barthelemy H, Chaby G, Gabison G, Perrot JL, Pallure V, Beneton N, Boye T, Jacobzone C, Begon E, Bernard P, Reguiai Z; sous l’égide de « ResoVerneil ». [Misdiagnosis of hidradenitis suppurativa continues to be a major issue. The R-ENS Verneuil study]. Ann Dermatol Venereol 2018;145:331-8. [PMID: 29704958 DOI: 10.1016/j.annder.2018.01.043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Turan E, Dogru O, Kargin S, Kerimoglu RS, Nazik EE. Crystallized phenol for sacral hidradenitis suppurativa. Journal of Dermatological Treatment 2021;32:193-6. [DOI: 10.1080/09546634.2019.1638878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Bouazzi D, Theut Riis P, Jemec GBE. Emergency Doctor's ability to diagnose Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2020;34:e712-4. [PMID: 32330318 DOI: 10.1111/jdv.16536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Willems D, Hiligsmann M, van der Zee HH, Sayed CJ, Evers SMAA. Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study. Patient 2021. [PMID: 34368925 DOI: 10.1007/s40271-021-00539-7] [Reference Citation Analysis]
13 Akdogan N, Yalici-Armagan B, Dogan S, Yılmaz R. Severe hidradenitis suppurativa (acne inversa) associated with focal segmental glomerulosclerosis and gout partially responsive to canakinumab. Dermatol Ther 2021;34:edth15002. [PMID: 34036700 DOI: 10.1111/dth.15002] [Reference Citation Analysis]
14 Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis. JAMA Dermatol 2021;157:924-31. [PMID: 34037678 DOI: 10.1001/jamadermatol.2021.1677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
15 Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol 2019;80:60-69.e2. [PMID: 29860040 DOI: 10.1016/j.jaad.2018.05.040] [Cited by in Crossref: 68] [Cited by in F6Publishing: 52] [Article Influence: 22.7] [Reference Citation Analysis]
16 Naik HB, Jo JH, Paul M, Kong HH. Skin Microbiota Perturbations Are Distinct and Disease Severity-Dependent in Hidradenitis Suppurativa. J Invest Dermatol 2020;140:922-925.e3. [PMID: 31539533 DOI: 10.1016/j.jid.2019.08.445] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
17 Haynes D, Hammer P, Malachowski SJ, Kaffenberger B, Yi JS, Vera N, Calhoun C, Shinohara MM, Seminario-Vidal L, Trinidad JC, Keller JJ, Ortega-Loayza AG. Characterisation and diagnosis of ulcers in inpatient dermatology consultation services: A multi-centre study. Int Wound J 2019;16:1440-4. [PMID: 31475449 DOI: 10.1111/iwj.13211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Wollina U, Brzezinski P, Koch A, Philipp-Dormston WG. Immunomodulatory drugs alone and adjuvant to surgery for hidradenitis suppurativa/acne inversa-A narrative review. Dermatol Ther 2020;33:e13877. [PMID: 32558202 DOI: 10.1111/dth.13877] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Thorlacius L, Ingram JR, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle R, Nielsen SM, Christensen R, Garg A, Jemec GBE; HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol 2018;179:642-50. [PMID: 29654696 DOI: 10.1111/bjd.16672] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 18.7] [Reference Citation Analysis]
20 Ardon CB, Molenaar C, van Straalen KR, Scholtes VC, Prens EP, van der Zee HH. High prevalence of hidradenitis suppurativa in patients with perianal fistula. Int J Colorectal Dis 2019;34:1337-9. [PMID: 31093736 DOI: 10.1007/s00384-019-03313-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol 2019;81:702-8. [PMID: 31095972 DOI: 10.1016/j.jaad.2019.05.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
22 Grimstad Ø, Tzellos T, Dufour DN, Bremnes Ø, Skoie IM, Snekvik I, Jarnaess E, Kyrgidis A, Ingvarsson G. Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG). J Eur Acad Dermatol Venereol 2019;33:1164-71. [PMID: 30451320 DOI: 10.1111/jdv.15353] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
23 Zouboulis CC. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa. Expert Review of Clinical Immunology 2016;12:1015-26. [DOI: 10.1080/1744666x.2016.1221762] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Morita A, Takahashi H, Ozawa K, Imafuku S, Takekuni N, Takahashi K, Matsuyama T, Okubo Y, Zhao Y, Kitamura S, Takei K, Yokoyama M, Hayashi N, Terui T. Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results. J Dermatol 2021;48:3-13. [PMID: 33029861 DOI: 10.1111/1346-8138.15605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
25 Thorlacius L, Garg A, Riis P, Nielsen S, Bettoli V, Ingram J, Marmol V, Matusiak L, Pascual J, Revuz J, Sartorius K, Tzellos T, Zee H, Zouboulis C, Saunte D, Gottlieb A, Christensen R, Jemec G. Inter‐rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. Br J Dermatol 2019;181:483-91. [DOI: 10.1111/bjd.17716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
26 Thorlacius L, Garg A, Ingram JR, Villumsen B, Theut Riis P, Gottlieb AB, Merola JF, Dellavalle R, Ardon C, Baba R, Bechara FG, Cohen AD, Daham N, Davis M, Emtestam L, Fernández-Peñas P, Filippelli M, Gibbons A, Grant T, Guilbault S, Gulliver S, Harris C, Harvent C, Houston K, Kirby JS, Matusiak L, Mehdizadeh A, Mojica T, Okun M, Orgill D, Pallack L, Parks-Miller A, Prens EP, Randell S, Rogers C, Rosen CF, Choon SE, van der Zee HH, Christensen R, Jemec GBE. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. Br J Dermatol 2018;178:715-21. [PMID: 29080368 DOI: 10.1111/bjd.16093] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
27 Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa. Journal of the American Academy of Dermatology 2020;82:1045-58. [DOI: 10.1016/j.jaad.2019.08.090] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 35.0] [Reference Citation Analysis]
28 Kirby JS, Butt M, Esmann S, Jemec GBE. Association of Resilience With Depression and Health-Related Quality of Life for Patients With Hidradenitis Suppurativa. JAMA Dermatol 2017;153:1263-9. [PMID: 29117300 DOI: 10.1001/jamadermatol.2017.3596] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
29 Shanmugam VK, Mulani S, McNish S, Harris S, Buescher T, Amdur R. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy. Int J Dermatol 2018;57:62-9. [PMID: 29130482 DOI: 10.1111/ijd.13798] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
30 Jørgensen A, Yao Y, Ghazanfar M, Ring H, Thomsen S. Burden, predictors and temporal relationships of comorbidities in patients with hidradenitis suppurativa: a hospital‐based cohort study. J Eur Acad Dermatol Venereol 2019;34:565-73. [DOI: 10.1111/jdv.15904] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
31 Andersen RK, Jemec GB. Treatments for hidradenitis suppurativa. Clin Dermatol 2017;35:218-24. [PMID: 28274363 DOI: 10.1016/j.clindermatol.2016.10.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
32 Vaienti S, Nazzaro G, Grancini A, Calzari P, Zaccaria G, Veraldi S, Vaienti L. Lymph Node Involvement in Axillary Hidradenitis Suppurativa: A Clinical, Ultrasonographic and Bacteriological Study Conducted during Radical Surgery. J Clin Med 2021;10:1433. [PMID: 33916058 DOI: 10.3390/jcm10071433] [Reference Citation Analysis]
33 Damiani G, Leone S, Fajgenbaum K, Bragazzi NL, Pacifico A, Conic RR, Pigatto PD, Maiorana C, Poli P, Berti E, Pace MC, Malagoli P, Bettoli V, Fiore M. Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis. World J Hepatol 2019;11:391-401. [PMID: 31114643 DOI: 10.4254/wjh.v11.i4.391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
34 Ovadja ZN, Zugaj M, Jacobs W, van der Horst CMAM, Lapid O. Recurrence Rates Following Reconstruction Strategies After Wide Excision of Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. Dermatol Surg 2021;47:e106-10. [PMID: 33795566 DOI: 10.1097/DSS.0000000000002815] [Reference Citation Analysis]
35 Sivanand A, Gulliver WP, Josan CK, Alhusayen R, Fleming PJ. Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review. J Cutan Med Surg 2020;24:64-72. [PMID: 31502868 DOI: 10.1177/1203475419874412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
36 Reddy S, Strunk A, Garg A. All-cause mortality among patients with hidradenitis suppurativa: A population-based cohort study in the United States. J Am Acad Dermatol 2019;81:937-42. [PMID: 31202872 DOI: 10.1016/j.jaad.2019.06.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Morita A, Takahashi H, Ozawa K, Imafuku S, Nakama T, Takahashi K, Matsuyama T, Okubo Y, Kitamura S, Matsuda N, Zhao Y, Yokoyama M, Hayashi N, Terui T. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa. J Dermatol 2019;46:745-51. [PMID: 31282051 DOI: 10.1111/1346-8138.14997] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
38 Kirsten N, Frings V, Nikolakis GD, Presser D, Goebeler M, Zouboulis CC, Augustin M. [Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa]. Hautarzt 2021;72:651-7. [PMID: 34223939 DOI: 10.1007/s00105-021-04851-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Thorlacius L, Cohen AD, Gislason GH, Jemec GB, Egeberg A. Increased Suicide Risk in Patients with Hidradenitis Suppurativa. Journal of Investigative Dermatology 2018;138:52-7. [DOI: 10.1016/j.jid.2017.09.008] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 23.3] [Reference Citation Analysis]
40 Loo CH, Tan WC, Tang JJ, Khor YH, Manikam MT, Low D, Chan KH, Chan KH, Teoh YM, Sohot NQA, Tang MM, Chan LC. The clinical, biochemical, and ultrasonographic characteristics of patients with hidradenitis suppurativa in Northern Peninsular Malaysia: a multicenter study. Int J Dermatol 2018;57:1454-63. [DOI: 10.1111/ijd.14210] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
41 Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Svensson A, Manolache L, Tzellos T, Sampogna F, Pustisek N, van der Zee HH, Marron SE, Spillekom-van Koulil S, Bewley A, Linder D, Abeni D, Szepietowski JC, Augustin M, Finlay AY. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2019;33:1633-43. [PMID: 31037773 DOI: 10.1111/jdv.15519] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
42 Akdogan N, Alli N, Uysal PI, Topcuoglu C, Candar T, Turhan T. Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case-control study. Arch Dermatol Res 2018;310:785-93. [PMID: 30293125 DOI: 10.1007/s00403-018-1867-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
43 Duchatelet S, Miskinyte S, Delage M, Ungeheuer MN, Lam T, Benhadou F, Del Marmol V, Vossen ARJV, Prens EP, Cogrel O, Beylot-Barry M, Girard C, Vidil J, Join-Lambert O, Parisot M, Nitschké P, Hanein S, Fraitag S, Van der Zee HH, Bessis D, Damiani G, Altomare A, Liao YH, Nikolakis G, Zouboulis CC, Nassif A, Hovnanian A. Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa. J Invest Dermatol 2020;140:2085-2088.e14. [PMID: 32142795 DOI: 10.1016/j.jid.2019.10.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
44 Krajewski PK, Szukała W, Lichawska-Cieślar A, Matusiak Ł, Jura J, Szepietowski JC. MCPIP1/Regnase-1 Expression in Keratinocytes of Patients with Hidradenitis Suppurativa: Preliminary Results. Int J Mol Sci 2021;22:7241. [PMID: 34298861 DOI: 10.3390/ijms22147241] [Reference Citation Analysis]
45 Ring HC, Thorsen J, Saunte DM, Lilje B, Bay L, Riis PT, Larsen N, Andersen LO, Nielsen HV, Miller IM, Bjarnsholt T, Fuursted K, Jemec GB. The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls. JAMA Dermatol 2017;153:897-905. [PMID: 28538949 DOI: 10.1001/jamadermatol.2017.0904] [Cited by in Crossref: 124] [Cited by in F6Publishing: 105] [Article Influence: 31.0] [Reference Citation Analysis]
46 Matusiak Ł, Jemec GB, Szepietowski JC. Pharmacological development in hidradenitis suppurativa. Current Opinion in Pharmacology 2019;46:65-72. [DOI: 10.1016/j.coph.2019.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
47 Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos‐bourboulis EJ, Fabbrocini G, Frew JW, Fujita H, González‐lópez MA, Guillem P, Gulliver WPF, Hamzavi I, Hayran Y, Hórvath B, Hüe S, Hunger RE, Ingram JR, Jemec GB, Ju Q, Kimball AB, Kirby JS, Konstantinou MP, Lowes MA, Macleod AS, Martorell A, Marzano AV, Matusiak Ł, Nassif A, Nikiphorou E, Nikolakis G, Nogueira da Costa A, Okun MM, Orenstein LA, Pascual JC, Paus R, Perin B, Prens EP, Röhn TA, Szegedi A, Szepietowski JC, Tzellos T, Wang B, van der Zee HH. What causes hidradenitis suppurativa ?—15 years after. Exp Dermatol 2020;29:1154-70. [DOI: 10.1111/exd.14214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 17.0] [Reference Citation Analysis]
48 Giamarellos-Bourboulis EJ, Bettoli V, Jemec GBE, Del Marmol V, Marzano AV, Prens EP, Tzellos T, Zouboulis CC. Anti-COVID-19 measurements for hidradenitis suppurativa patients. Exp Dermatol 2021;30 Suppl 1:18-22. [PMID: 34085330 DOI: 10.1111/exd.14339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Çetinarslan T, Türel Ermertcan A, Özyurt B, Gündüz K. Evaluation of the laboratory parameters in hidradenitis suppurativa: Can we use new inflammatory biomarkers? Dermatol Ther 2021;34:e14835. [PMID: 33527638 DOI: 10.1111/dth.14835] [Reference Citation Analysis]
50 Magalhães RF, Rivitti-Machado MC, Duarte GV, Souto R, Nunes DH, Chaves M, Hirata SH, Ramos AMC. Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology. An Bras Dermatol 2019;94:7-19. [PMID: 31166401 DOI: 10.1590/abd1806-4841.20198607] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
51 Kjærsgaard Andersen R, Jørgensen IF, Reguant R, Jemec GBE, Brunak S. Disease Trajectories for Hidradenitis Suppurativa in the Danish Population. JAMA Dermatol 2020;156:780-6. [PMID: 32432647 DOI: 10.1001/jamadermatol.2020.1281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
52 Bouazzi D, Chafranska L, Saunte DML, Jemec GBE. Systematic Review of Complications and Recurrences After Surgical Interventions in Hidradenitis Suppurativa. Dermatol Surg 2020;46:914-21. [PMID: 32049703 DOI: 10.1097/DSS.0000000000002323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
53 Argyropoulou M, Kanni T, Kyprianou M, Melachroinopoulos N, Giamarellos‐bourboulis E. Cost‐savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real‐world cohort. Br J Dermatol 2019;180:1161-8. [DOI: 10.1111/bjd.17151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
54 Fincher JA, Jones DR, Korte AR, Dyer JE, Parlanti P, Popratiloff A, Brantner CA, Morris NJ, Pirlo RK, Shanmugam VK, Vertes A. Mass Spectrometry Imaging of Lipids in Human Skin Disease Model Hidradenitis Suppurativa by Laser Desorption Ionization from Silicon Nanopost Arrays. Sci Rep 2019;9:17508. [PMID: 31767918 DOI: 10.1038/s41598-019-53938-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
55 Thorlacius L, Esmann S, Miller I, Vinding G, Jemec GBE. Development of HiSQOL: A Hidradenitis Suppurativa-Specific Quality of Life Instrument. Skin Appendage Disord 2019;5:221-9. [PMID: 31367600 DOI: 10.1159/000496234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
56 Isoherranen K, O'brien JJ, Barker J, Dissemond J, Hafner J, Jemec GBE, Kamarachev J, Läuchli S, Montero EC, Nobbe S, Sunderkötter C, Velasco ML. Atypical wounds. Best clinical practice and challenges. J Wound Care 2019;28:S1-S92. [DOI: 10.12968/jowc.2019.28.sup6.s1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
57 Nguyen T, Damiani G, Orenstein L, Hamzavi I, Jemec G. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021;35:50-61. [DOI: 10.1111/jdv.16677] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 23.0] [Reference Citation Analysis]
58 Vaiopoulos AG, Nikolakis G, Zouboulis CC. Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature. J Eur Acad Dermatol Venereol 2020;34:2140-6. [PMID: 32324936 DOI: 10.1111/jdv.16520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
59 Kanni T, Argyropoulou M, Spyridopoulos T, Pistiki A, Stecher M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ. MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. J Invest Dermatol 2018;138:795-801. [PMID: 29129600 DOI: 10.1016/j.jid.2017.10.030] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
60 Nikolakis G, Kyrgidis A, Zouboulis CC. Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data. Am J Clin Dermatol 2019;20:503-13. [DOI: 10.1007/s40257-019-00442-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
61 Li C, Li W, Xu H, Zhang X, Su B, Zhang W, Zhang X, Wang B. PSENEN Mutation Carriers with Co-manifestation of Acne Inversa (AI) and Dowling-Degos Disease (DDD): Is AI or DDD the Subphenotype? J Invest Dermatol 2017;137:2234-6. [PMID: 28601418 DOI: 10.1016/j.jid.2017.05.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
62 Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, Ingram JR, Kanni T, Karagiannidis I, Martorell A, Matusiak Ł, Pinter A, Prens EP, Presser D, Schneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R; European Hidradenitis Suppurativa Foundation Investigator Group. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017;177:1401-9. [PMID: 28636793 DOI: 10.1111/bjd.15748] [Cited by in Crossref: 117] [Cited by in F6Publishing: 89] [Article Influence: 29.3] [Reference Citation Analysis]
63 Bianchi L, Caposiena Caro RD, Ganzetti G, Molinelli E, Dini V, Oranges T, Romanelli M, Fabbrocini G, Monfrecola G, Napolitano M, Egan CG, Musumeci ML, Lacarrubba F, Micali G, Passoni E, Calzavara-Pinton PG, Venturini M, Zanca A, Offidani AM. Sex-related differences of clinical features in hidradenitis suppurativa: analysis of an Italian-based cohort. Clin Exp Dermatol 2019;44:e177-80. [PMID: 30593710 DOI: 10.1111/ced.13861] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
64 Ring HC, Bay L, Nilsson M, Kallenbach K, Miller IM, Saunte DM, Bjarnsholt T, Tolker-Nielsen T, Jemec GB. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol 2017;176:993-1000. [PMID: 27564400 DOI: 10.1111/bjd.15007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 40] [Article Influence: 14.3] [Reference Citation Analysis]
65 Theut Riis P, Thorlacius LR, Jemec GB. Investigational drugs in clinical trials for Hidradenitis Suppurativa. Expert Opin Investig Drugs 2018;27:43-53. [PMID: 29188733 DOI: 10.1080/13543784.2018.1412430] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
66 Akdogan N, Dogan S, Incel-uysal P, Karabulut E, Topcuoglu C, Yalcin B, Atakan N. Serum amyloid A and C-reactive protein levels and erythrocyte sedimentation rate are important indicators in hidradenitis suppurativa. Arch Dermatol Res 2020;312:255-62. [DOI: 10.1007/s00403-019-02014-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Sanchez-Diaz M, Martinez-Lopez A, Salvador-Rodriguez L, Montero-Vilchez T, Arias-Santiago S, Molina-Leyva A. The role of biologic treatment in special scenarios in hidradenitis suppurativa: Facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema. Dermatol Ther 2021;34:e14829. [PMID: 33527618 DOI: 10.1111/dth.14829] [Reference Citation Analysis]
68 Zouboulis CC, Goyal M. Hidradenitis Suppurativa. In: Orfanos CE, Zouboulis CC, Assaf C, editors. Pigmented Ethnic Skin and Imported Dermatoses. Cham: Springer International Publishing; 2018. pp. 219-28. [DOI: 10.1007/978-3-319-69422-1_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Br J Dermatol 2019;181:967-75. [PMID: 30916379 DOI: 10.1111/bjd.17919] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
70 Sarfo A, Butt M, Kirby J. Periodic worsening, or flare, in hidradenitis suppurativa: the perspective of people with hidradenitis. Br J Dermatol 2019. [DOI: 10.1111/bjd.18210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
71 Theut Riis P, Saunte D, Benhadou F, del Marmol V, Guillem P, El-domyati M, Abdel-wahab H, Antoniou C, Dessinioti C, Gürer M, Beksaç B, Szepietowski J, Matusiak L, Emtestam L, Lapins J, Riad H, Doss N, Massa A, Hamzavi I, Nicholson C, Dolenc-voljc M, Kim K, Ohn J, Zouboulis C, Karagiannidis I, Mokos Z, Durinec P, Jemec G. Low and high body mass index in hidradenitis suppurativa patients-different subtypes? J Eur Acad Dermatol Venereol 2018;32:307-12. [DOI: 10.1111/jdv.14599] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
72 Hessam S, Scholl L, Sand M, Schmitz L, Reitenbach S, Bechara FG. A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa. JAMA Dermatol 2018;154:330-5. [PMID: 29417136 DOI: 10.1001/jamadermatol.2017.5890] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
73 Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, Zemskov SV, Abeni D, Tzellos T, Szepietowski JC, Zouboulis CC. Quality of Life in Hidradenitis Suppurativa: An Update. Int J Environ Res Public Health 2021;18:6131. [PMID: 34204126 DOI: 10.3390/ijerph18116131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
74 Miller IM, Vinding G, Sørensen HA, Rytgaard H, Mogensen UB, Ellervik C, Jemec GB. Thyroid function in hidradenitis suppurativa: a population-based cross-sectional study from Denmark. Clin Exp Dermatol 2018;43:899-905. [DOI: 10.1111/ced.13606] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
75 Thorlacius L, Riis PT, List EK, Christensen R, Jemec GBE. Sub-classification of Hidradenitis suppurativa: a cross-sectional study. Arch Dermatol Res 2020. [PMID: 33089403 DOI: 10.1007/s00403-020-02149-z] [Reference Citation Analysis]
76 Fisher S, Jehassi A, Ziv M. Hidradenitis suppurativa on Facebook: thematic and content analyses of patient support group. Arch Dermatol Res 2020;312:421-6. [PMID: 31845011 DOI: 10.1007/s00403-019-02027-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
77 Martorell A, Wortsman X, Alfageme F, Roustan G, Arias-Santiago S, Catalano O, Scotto di Santolo M, Zarchi K, Bouer M, Gaitini D, Gonzalez C, Bard R, García-Martínez FJ, Mandava A. Ultrasound Evaluation as a Complementary Test in Hidradenitis Suppurativa: Proposal of a Standarized Report. Dermatol Surg 2017;43:1065-73. [PMID: 28538033 DOI: 10.1097/DSS.0000000000001147] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 9.3] [Reference Citation Analysis]
78 Nikolakis G, von Stebut E. [Topical and novel device-based therapies for mild hidradenitis suppurativa]. Hautarzt 2021;72:676-85. [PMID: 34223936 DOI: 10.1007/s00105-021-04849-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Smith MK, Nicholson CL, Parks-Miller A, Hamzavi IH. Hidradenitis suppurativa: an update on connecting the tracts. F1000Res. 2017;6:1272. [PMID: 28794864 DOI: 10.12688/f1000research.11337.1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
80 Oranges T, Vitali S, Benincasa B, Izzetti R, Lencioni R, Caramella D, Romanelli M, Dini V. Advanced evaluation of hidradenitis suppurativa with ultra‐high frequency ultrasound: A promising tool for the diagnosis and monitoring of disease progression. Skin Res Technol 2020;26:513-9. [DOI: 10.1111/srt.12823] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
81 Pink A, Anzengruber F, Navarini A. Acne and hidradenitis suppurativa. Br J Dermatol 2018;178:619-31. [DOI: 10.1111/bjd.16231] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
82 Zouboulis C, Nogueira da Costa A, Fimmel S, Zouboulis K. Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific. J Eur Acad Dermatol Venereol 2020;34:1555-63. [DOI: 10.1111/jdv.16264] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
83 Andrade TCPC, Vieira BC, Oliveira AMN, Martins TY, Santiago TM, Martelli ACC. Hidradenitis suppurativa: epidemiological study of cases diagnosed at a dermatological reference center in the city of Bauru, in the Brazilian southeast State of São Paulo, between 2005 and 2015. An Bras Dermatol 2017;92:196-9. [PMID: 28538878 DOI: 10.1590/abd1806-4841.20175588] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
84 Lacarrubba F, Dini V, Napolitano M, Venturini M, Caposiena Caro D, Molinelli E, Passoni E, Monfrecola G, Argenziano G, Berti E, Bianchi L, Calzavara Pinton P, Cannavò SP, Costanzo A, Donini M, Fabbrocini G, Fierro MT, Micali G, Offidani A, Parodi A, Patrizi A, Pellacani G, Peris K, Pimpinelli N, Potenza C, Romanelli M, Rongioletti F, Solivetti F; the Italian Ultrasound Working Group. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience. J Eur Acad Dermatol Venereol 2019;33:10-4. [DOI: 10.1111/jdv.15847] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
85 Tzellos T, Zouboulis CC. Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice. Dermatol Ther (Heidelb) 2020;10:63-71. [PMID: 31955366 DOI: 10.1007/s13555-020-00354-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
86 He Y, Xu H, Li C, Zhang X, Zhou P, Xiao X, Zhang W, Wu Y, Zeng R, Wang B. Nicastrin/miR-30a-3p/RAB31 Axis Regulates Keratinocyte Differentiation by Impairing EGFR Signaling in Familial Acne Inversa. J Invest Dermatol 2019;139:124-34. [PMID: 30120935 DOI: 10.1016/j.jid.2018.07.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
87 Shavit E, Alavi A, Bechara FG, Bennett RG, Bourcier M, Cibotti R, Daveluy S, Frew JW, Garg A, Hamzavi I, Hoffman LK, Hsaio J, Kirby JS, Lev-Tov H, Martinez E, Micheletti R, Naik HB, Nassif A, Nicholson C, Parks-Miller A, Patel Z, Piguet V, Ramesh M, Resnik B, Sayed C, Schultz G, Siddiqui A, Tan J, Wortsman X, Lowes MA. Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017. Exp Dermatol 2019;28:94-103. [PMID: 30484907 DOI: 10.1111/exd.13849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
88 Yüksel M, Basım P. Demographic and Clinical Features of Hidradenitis Suppurativa in Turkey. J Cutan Med Surg 2020;24:55-9. [DOI: 10.1177/1203475419887732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
89 Derruau S, Gobinet C, Untereiner V, Sockalingum GD, Nassif A, Viguier M, Piot O, Lorimier S. New insights into hidradenitis suppurativa diagnosis via salivary infrared biosignatures: A pilot study. J Biophotonics 2021;14:e202000327. [PMID: 33231348 DOI: 10.1002/jbio.202000327] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Ring HC, Thorsen J, Saunte DM, Lilje B, Bay L, Theut Riis P, Larsen N, O'Brien Andersen L, Vedel Nielsen H, Miller IM, Bjarnsholt T, Fuursted K, Jemec GB. Moderate to severe hidradenitis suppurativa patients do not have an altered bacterial composition in peripheral blood compared to healthy controls. J Eur Acad Dermatol Venereol 2018;32:125-8. [PMID: 28833590 DOI: 10.1111/jdv.14538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
91 Nikolakis G, Join-Lambert O, Karagiannidis I, Guet-Revillet H, Zouboulis CC, Nassif A. Bacteriology of hidradenitis suppurativa/acne inversa: A review. J Am Acad Dermatol 2015;73:S12-8. [PMID: 26470608 DOI: 10.1016/j.jaad.2015.07.041] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
92 Durán-Vian C, Arias-Loste MT, Hernández JL, Fernández V, González M, Iruzubieta P, Rasines L, González-Vela C, Vaqué JP, Blanco R, Crespo J, González-López MA. High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors. J Eur Acad Dermatol Venereol 2019;33:2131-6. [PMID: 31260574 DOI: 10.1111/jdv.15764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
93 Nielsen RM, Lindsø Andersen P, Sigsgaard V, Theut Riis P, Jemec GB. Pain perception in patients with hidradenitis suppurativa. Br J Dermatol 2020;182:166-74. [PMID: 30919930 DOI: 10.1111/bjd.17935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
94 Pascual J, González I, Corona D, Hispán P, Ramos J, Sánchez-paya J, Jemec G. Assessment of subclinical atherosclerosis in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2017;31:1229-38. [DOI: 10.1111/jdv.14076] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
95 Tavora IG, Bissoli GC, Miot HA, Schmitt JV. Clinical manifestations and quality of life in hidradenitis suppurativa patients: survey of participants from an internet support group. An Bras Dermatol 2019;94:298-303. [PMID: 31365658 DOI: 10.1590/abd1806-4841.20197687] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
96 Jemec GB. Commentary on Ultrasound Evaluation as a Complementary Test in Hidradenitis Suppurativa. Dermatol Surg 2017;43:1074-5. [DOI: 10.1097/dss.0000000000001153] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Ovadja ZN, Jacobs W, Zugaj M, van der Horst CM, Lapid O. Recurrence Rates Following Excision of Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. Dermatol Surg 2020;46:e1-7. [DOI: 10.1097/dss.0000000000002403] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
98 Nikolakis G, Kokolakis G, Kaleta K, Wolk K, Hunger R, Sabat R, Zouboulis CC. [Pathogenesis of hidradenitis suppurativa/acne inversa]. Hautarzt 2021;72:658-65. [PMID: 34228138 DOI: 10.1007/s00105-021-04853-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Ring HC, Theut Riis P, Zarchi K, Miller IM, Saunte DM, Jemec GB. Prodromal symptoms in hidradenitis suppurativa. Clin Exp Dermatol 2017;42:261-5. [DOI: 10.1111/ced.13025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
100 Dauden E, Lazaro P, Aguilar M, Blasco A, Suarez C, Marin I, Queiro R, Bassas-vila J, Martorell A, García-campayo J. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2018;32:129-44. [DOI: 10.1111/jdv.14517] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
101 Ring HC, Sigsgaard V, Thorsen J, Fuursted K, Fabricius S, Saunte DM, Jemec GB. The microbiome of tunnels in hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol 2019;33:1775-80. [PMID: 30908704 DOI: 10.1111/jdv.15597] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
102 Eşer E, Engin B, Yüksel P, Kocazeybek BS, Kutlubay Z, Serdaroğlu S, Aşkın Ö. Relationship between fecal calprotectin level and disease activity in patients with hidradenitis suppurativa. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.13232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Zouboulis CC, Goyal M, Byrd AS. Hidradenitis suppurativa in skin of colour. Exp Dermatol 2021;30 Suppl 1:27-30. [PMID: 34085333 DOI: 10.1111/exd.14341] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Ghias MH, Johnston AD, Kutner AJ, Micheletti RG, Hosgood HD, Cohen SR. High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. Journal of the American Academy of Dermatology 2020;82:1094-101. [DOI: 10.1016/j.jaad.2019.09.071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 23.0] [Reference Citation Analysis]
105 Zouboulis CC, Nogueira da Costa A, Makrantonaki E, Hou XX, Almansouri D, Dudley JT, Edwards H, Readhead B, Balthasar O, Jemec GBE, Bonitsis NG, Nikolakis G, Trebing D, Zouboulis KC, Hossini AM. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2020;34:846-61. [PMID: 31838778 DOI: 10.1111/jdv.16147] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
106 Napolitano M, Calzavara-pinton P, Zanca A, Bianchi L, Caposiena Caro R, Offidani A, Ganzetti G, Molinelli E, Dini V, Oranges T, Romanelli M, Egan C, Fabbrocini G, Monfrecola G, Lacarrubba F, Musumeci M, Passoni E, Venturini M, Micali G. Comparison of clinical and ultrasound scores in patients with hidradenitis suppurativa: results from an Italian ultrasound working group. J Eur Acad Dermatol Venereol 2019;33:e84-7. [DOI: 10.1111/jdv.15235] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
107 Benhadou F, Van der Zee H, Pascual J, Rigopoulos D, Katoulis A, Liakou A, Daxhelet M, Romanelli M, Iannone M, Kinyó Á, Nikolakis G, Zouboulis C, Dessinioti C, Zisimou C, Antoniou C, Alavi A, Mintoff D, Aquilina S, Matusiak L, Szepietowski J, Sinclair R, Husein‐elahmed H, von Laffert M, Revuz J, Danby B, Puig L, Theut Riis P, Jemec G, Straalen K, Wigny K, Marmol V, Guillem P. Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross‐sectional study among 2465 patients. Br J Dermatol 2019;181:1198-206. [DOI: 10.1111/bjd.17927] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]